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Abstract
Background: Tuberculosis (TB) kills approximately two million people and infects around nine million worldwide
annually. Its proper management, especially in resource-limited settings, has been hindered by the lack of rapid and
easy-to-use diagnostic tests. Sputum smear microscopy remains the cheapest, readily available diagnostic method
but it only identifies less than half of the patients with a HIV/TB co-infection because the bacilli would have
disseminated from the lungs to other areas of the body. The fully automated Xpert® MTB/RIF assay is a promising
innovation for diagnosing TB and detecting resistance to rifampicin. This study aimed to evaluate the use of Xpert®
MTB/RIF assay and microscopy in the diagnosis of Mycobacterium tuberculosis in Namibia, by determining the
disease’s epidemiology and calculating the proportion of cases infected just with TB and those with a resistance to
rifampicin among the total suspected cases of TB in the country.
Methods: This retrospective study analysed TB cases that were diagnosed using both the Xpert® MTB/RIF assay and
microscopy. Data were collected from patient records from the Meditech laboratory information system of the
Namibia Institute of Pathology for the time period of July 2012–April 2013. Data from 13 regions were collected.
Results: The total number of specimens collected from patients with symptoms of pulmonary TB was 1 842. Of
these, 594 (32.20%) were found to be positive for MTB by Xpert® MTB/RIF assay, out of which 443 (24.05%) were
also found to be positive by microscopy. The remainder was negative. The male patients were more resistant to
rifampicin when compared to the female patients.
Conclusions: Tuberculosis is widely distributed throughout Namibia, with slightly more males infected than
females. Most TB patients are also co-infected with HIV. Both microscopy and Xpert® MTB/RIF assay are crucial for
the diagnosis of TB in the country. Screening diagnostic efforts should focus on the sexually active HIV positive
male population who could be the source of more RIF-resistant TB than females to prevent its spread.
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Background
Tuberculosis (TB), an infection that mainly affects the
lungs, is caused by Mycobacterium tuberculosis (MTB).
The infection can be diagnosed by sputum smear
microscopy, chest radiography, culture-based testing, or
nucleic acid amplification tests (NAATs) [1, 2]. Recently,
new diagnostic techniques have been discovered, includ-
ing interferon-gamma release assays and Xpert® MTB/
RIF assay [3].
The elimination of TB requires improved detection
and early treatment. Many people still die from TB due
to delayed diagnosis and this contributes to the risk of
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TB transmission [4]. Microscopy with Ziehl-Neelsen
(ZN) staining is the most common and often the only
laboratory technique used to diagnose TB in most devel-
oping countries [1, 5–8]. However, errors associated with
microscopy lead to misdiagnoses [6]. It is therefore vital
to improve and possibly replace microscopy with sim-
pler, more affordable, and more accurate diagnostic
methods. Patients who are co-infected with HIV are
often the ones whose smear results are negative, when in
fact they actually have TB [9]. This is because the bacilli
would have disseminated from the lungs to other organs
due to immunosuppression. If facilities are available, it
would be best to use the gold standard of diagnosing
pulmonary TB using culture-based testing in HIV posi-
tive patients [10].
GeneXpert is a system based on a NAAT that rapidly
diagnoses and detects MTB and rifampicin (RIF) resist-
ance in clinical specimens [4, 9, 11]. The World Health
Organization endorsed it as the initial diagnostic test
for individuals suspected of having multidrug-resistant
TB (MDR-TB) or HIV-associated TB [7, 12, 13]. How-
ever, Xpert® MTB/RIF assay cannot completely elimin-
ate the need for microscopy and culture, as the latter
are essential for the detection of resistance to drugs
other than RIF [14].
Namibia is the country with the fourth highest TB
burden in the world. The incidence rate in 2015 was
651/100 000 [15]. Cases of TB in Namibia are widely
distributed throughout the country, however, the major-
ity of cases are reported in the regions of Khomas,
Ohangwena, Erongo, and Kavango [15, 16]. Currently,
the public health reference diagnostic laboratory, the
Namibia Institute of Pathology (NIP), uses ZN micros-
copy, Xpert® MTB/RIF assay, and, to a lesser extent, TB
culture to diagnose TB.
The aim of the study was to evaluate the use of ZN
microscopy and Xpert® MTB/RIF assay for the diagnosis
of TB cases in Namibia. This was done by determining
the disease’s epidemiology and calculating the propor-
tion of TB positive cases and cases with resistance to
RIF among the sputum samples stored at the NIP in
Windhoek.
Methods
Study design and setting
This was a retrospective study that analyzed MTB cases
diagnosed using both the Xpert® MTB/RIF assay (Cepheid,
Sunnyvale, CA, USA) and microscopy. Data were col-
lected from patient records that were retrieved from the
Meditech laboratory information system of the NIP for
the period of July 2012–April 2013. The records came
from all 13 regions of Namibia, but excluded data from
private hospitals and clinics. The specimens were tested
for acid-fast bacilli using microscopy and Xpert® MTB/RIF
assay within three days of being received by the laboratory.
The total number of specimens collected from patients
with symptoms of pulmonary TB was 1 842.
Data collection
The data extracted included: HIV status based on the
Determine™ HIV-1/2 test (Alere, Milan, Italy), laboratory
number, age, sex, positive and negative results from
microscopy and Xpert® MTB/RIF assay testing, and the
patient’s region as indicated by the given residential ad-
dress. Data were entered and sorted using Microsoft
Excel before being analyzed using IBM SPSS version
21.0 (SPSS Inc., Chicago, Illinois, USA). If the p-value
was less than 0.05, this was considered as significant.
Findings
Cases were categorized as either sputum smear-positive
or sputum smear-negative. They were also categorized
as either Xpert® MTB/RIF assay positive or Xpert® MTB/
RIF assay negative, based on the assay results. Out of the
1 842 specimens tested, 594 (32.20%) were found to be
positive for MTB by Xpert® MTB/RIF assay, and of those
443 (24.05%) were also found to be positive by microscopy.
The remainder was negative.
Table 1 summarizes the numbers of MTB cases detected
by microscopy in the 13 regions of Namibia with regard
to sex. Khomas had the highest number of MTB cases,
followed by Oshana and Ohangwena. The lowest numbers
of cases were recorded in Zambezi and Omaheke. The
specific regions where fifteen women resided were not
indicated in the data set and hence were missing. We also
Table 1 Positive MTB cases detected by microscopy in Namibia
from July 2012 to April 2013, by region and sex
Region Sex Total
Male Female
No. % No. % No %
Khomas 28 14.7 47 18.9 75 17.1
Kavango 19 10.0 12 4.8 31 7.1
Oshikoto 32 16.8 22 8.8 54 12.3
Ohangwena 25 13.2 34 13.7 59 13.4
Kunene 2 1.1 4 1.6 6 1.4
llKaras 10 5.3 10 5.3 31 7.1
Oshana 25 13.2 48 19.3 73 16.6
Otjozondjupa 5 2.6 11 4.4 16 3.6
Erongo 11 5.8 11 4.4 22 5
Hardap 4 2.1 10 4 14 3.2
Omusati 25 13.2 27 10.8 52 11.1
Zambezi 2 1.1 0 0 2 0.5
Omaheke 2 1.1 2 0.8 4 0.9
Total 190 100 238 100 428 100
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compared the results from the smear microscopy by sex.
Microscopy detected that there were slightly more males
with MTB than females. The P-value obtained using the
chi-square test was 0.489, indicating that there was no
significant association between smear microscopy and sex.
The majority of the patients belonged to the age
groups of 20–40 years and 41–60 years. In the age group
of above 60 years, there was a lower number of MTB
cases, but the lowest number of MTB cases was re-
corded among the age group of below 20 years (see
Table 2). Data on the age of four patients were not avail-
able because it was missing from the data set. Of the
total 249 MTB-positive males, 190 (76.3%) tested posi-
tive for MTB using both methods and the rest tested
positive by Xpert® MTB/RIF assay only. Out of the fe-
males, 238 (95.2%) tested positive for MTB using both
methods, with an extra 12 testing positive using Xpert®
MTB/RIF assay only.
Of the total positive MTB cases, 341 (57.4%) patients
also tested positive for HIV and 137 (23.1%) tested nega-
tive for HIV. The HIV status of the remaining 116
(19.5%) patients was unknown (see Table 3). Patients in
the age groups of 20–40 years and 41–60 years were
found to be the most co-infected with MTB/HIV (45.7%
and 49.0% HIV, respectively). Only 18 (5.3%) of the total
HIV-positive patients belonged to the age group of
above 60 years. There were no HIV-positive patients
among the age group of below 20 years.
Table 4 summarizes the distribution of HIV in MTB-
infected patients, by sex. A higher percentage of HIV-
positive males (63.9%) as compared to females (52.8%)
was recorded.
The number of MTB cases and RIF-resistant cases
diagnosed using the Xpert® MTB/RIF assay with regard
to sex is presented in Table 5. From the total of 594
MTB-positive patients, 27.9% were resistant to RIF and
72.1% were sensitive to it. More males were found to be
resistant to RIF as compared to the females, with the
difference statistically significant (P = 0.023).
Discussion
A total of 594 specimens tested positive for MTB
using the Xpert® MTB/RIF assay, and of these 443
(74.6%) also tested positive using smear microscopy.
These data indicate that smear microscopy detected
TB in fewer patients than Xpert® MTB/RIF assay.
Smear microscopy might miss specimens with low
bacilli/ml, as direct smear microscopy needs at least 5
000 bacilli/ml of sputum for direct microscopy to
show a positive result [1, 11].
In the current study, there were slightly more females
with stronger smear-positivity than males and the differ-
ence was not statistically significant. Although culture-
based testing is the gold standard for TB diagnosis, it
needs high-safety settings and facilities that are expen-
sive to maintain, and this means that most low- and
middle- income countries cannot afford to do this kind
of testing. For this reason, sputum smear microscopy
remains the main and often only diagnostic tool for
MTB [6–8, 17, 18]. Tuberculosis culture for drug-
Table 2 Comparison of sputum smear-positive results and
positive Xpert® MTB/RIF assay results, by age
Age group Xpert® result
Positive
No. %
Below 20 years Sputum smear-positive 10 62.5
Total 16 100.0
Between 20 and 40 years Sputum smear-positive 210 78.9
Total 266 100.0
Between 40 and 60 years Sputum smear-positive 169 71.3
Total 237 100.0
Above 60 years Sputum smear-positive 51 71.8
Total 71 100.0
Total (defined as Xpert® positive) 440 74.6
Total 590 100.0
Table 3 Comparison of sputum smear-positive and Xpert® MTB/
RIF assay results, by HIV status
HIV Status Within Xpert® result
Positive
No. %
Positive Sputum smear-positive 263 77.1
Total 341 100.0
Negative Sputum smear-positive 102 74.5
Total 137 100.0
Unknown Sputum smear-positive 78 67.2
Total 116 100.0
Total (defined as Xpert® positive) 443 74.6
Total 594 100.0
Table 4 HIV co-infection in MTB-infected patients diagnosed




Male No. 159 45 45 249
% 63.9 18.1 18.1 100.0
Female No. 182 92 71 345
% 52.8 26.7 20.5 100.0
Total No. 341 137 116 594
% 57.4 23.1 19.5 100.0
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susceptibility testing is not routinely performed in
Namibia [19]. Culture-based testing is also quite time-
consuming, requiring more than eight weeks for results
to become available. However, the Xpert® MTB/RIF
assay gives accurate results in a shorter time period of
less than 2 h and being cheaper than culture is therefore
more appropriate for use in low- and middle-income
countries [20]. That being said, it cannot completely
replace culture-based testing, as it only detects RIF
resistance and does not provide drug resistance profiles
for other TB drugs. Namibia needs to scale up its facil-
ities for culture-based testing so that specimens that are
found to be RIF-resistant are further tested for MDR-TB
and extensively drug-resistant (XDR) TB. This will assist
in guiding treatment regimens for patients who might
have MDR-TB or XDR TB.
This study found that MTB infection is distributed
throughout Namibia, with males slightly more infected
than females. Khomas was the region with the highest
number of MTB cases, whereas Zambezi and Omaheke
had the lowest numbers of MTB cases (each). This is
similar to findings from a previous study, which also
showed that TB was distributed all over Namibia with
the highest number of cases reported in Khomas and
Okavango [16]. Khomas had the highest number of
MTB cases possibly because of its central location,
which includes the densely populated capital city
Windhoek, where there is also a high HIV prevalence.
HIV predisposes patients to TB. This region is receiving
information on MTB testing awareness from different
health-related stakeholders, which likely resulted in
more people with TB getting tested once they suspected
that they had TB symptoms. Zambezi and Omaheke
recorded fewer MTB-positive patients probably due to
their remote locations. Those who could be TB positive
rarely have the information that could make them
question or suspect that they are TB positive.
This study found that the age group with the highest
MTB infection were those aged between 20 and 40 years
(44.8%). The age group of below 20 years had the least
amount of people with MTB infection (2.7%). The low
infection rate in the younger age group could possibly
be explained by this age group’s literacy, which allows
them to effectively receive educational information on
MTB prevention from schools and the media.
The study found a high MTB/HIV co-infection rate of
57.4% emphasizing the need for proactive and rapid
screening of MTB/HIV co-infected patients. The num-
ber of patients with MTB/HIV in the age groups of 20–
40 years was found to be high because the age group is
considered a sexually active age group, with members
having an increased risk of contracting HIV through
unsafe sex [21]. Most of the HIV-positive patients in our
study belonged to that age group.
Xpert® MTB/RIF assay is an important initial diagnos-
tic test for patients suspected of having MDR-TB and
those with a MTB/HIV co-infection [18]. An association
between sex and sensitivity to RIF was noted. A smaller
number of females was infected with a RIF-resistant
strain than males possibly because females better adhere
to drug taking than males. Fewer females than males are
known to take alcohol or drugs in Namibia which often
contributes to poor drug adherence. However, there
could also be other reasons for this such as TB transmis-
sion mechanisms, primary versus secondary drug resist-
ance, different co-infections, and different health-seeking
behaviors. For instance men tend to socialize in crowded
places than females such that they are likely to get
community-acquired resistant strains. Further investiga-
tions are therefore needed. In 2014, only 137 cases of
MDR-TB have been reported, indicating that drug
susceptibility testing is improving in Namibia [15].
Conclusions
Tuberculosis is widely distributed throughout Namibia,
with more males infected than females. Males have more
resistance to RIF than females. Tuberculosis infection
was mainly common in the age group of 20–40 years. A
large proportion of MTB patients were also infected
with HIV. Microscopy and Xpert® MTB/RIF assay are
both crucial MTB diagnostic tools in areas of high HIV
incidence. Screening diagnostic efforts should focus on
the sexually active male HIV positive population who
could be the source of more RIF-resistant TB than
females to prevent its spread.
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Male No. 86 163 249
% 34.5 65.5 100
Female No. 80 265 345
% 23.8 76.2 100
Total No. 166 428 594
% 27.9 72.1 100
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